Barinthus Bio Q1 net loss narrows to $5.5M; merger with Clywedog on track

Barinthus Biotherapeutics plc.

2026-Q1 EPS reported -$0.14

Net loss of $5.5M ($0.14/shr) vs $19.6M ($0.49/shr) in Q1 2025.
Cash $67.2M at March 31, 2026; post-merger cash runway expected through 2027.
Merger with Clywedog expected mid-2026; combined company to trade as CLYD.
Doug Swirsky appointed CFO effective May 1, 2026.
VTP-1000 celiac trial data from multiple ascending dose portion expected H2 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Barinthus Biotherapeutics plc. reported quarter ended March 31, 2026 results: net income net loss attributable to its shareholders of $5.5 million, or $(0.14) per share, EPS $(0.14) per share.

Period: quarter ended March 31, 2026
Net income: net loss attributable to its shareholders of $5.5 million, or $(0.14) per share
EPS: $(0.14) per share
Result: reported results

Exact text from the filing

For the first quarter of 2026, the Company generated a net loss attributable to its shareholders of $5.5 million, or $(0.14) per share on both basic and fully diluted bases

View on SEC.gov

1431 earnings releases filed in the last 30 days. Browse all earnings releases →

Barinthus Biotherapeutics plc. filing history →

Source: SEC EDGAR

accession 0001828185-26-000018

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.